Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2757777 | 1.00 | MMP9 (0.32) | MMP9MMP1MMP2 | |
| SCHEMBL6765429 | 0.88 | MMP9 (0.34) | MMP9MMP1MMP2 | |
| SCHEMBL2871627 | 0.86 | MMP9 (0.32) | MMP9MMP1MMP2 | |
| SCHEMBL12325580 | 0.84 | — | — | |
| SCHEMBL14429313 | 0.83 | — | — | |
| SCHEMBL13381148 | 0.81 | MMP9 (0.31) | MMP9MMP1MMP2 | |
| SCHEMBL6765481 | 0.80 | MMP9 (0.31) | MMP9MMP1MMP2 | |
| SCHEMBL23198114 | 0.78 | MEN1 (0.36) | — | |
| SCHEMBL23220911 | 0.78 | MEN1 (0.36) | — | |
| SCHEMBL13381185 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835734-B2 | (S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals, useful as intermediates for the preparation of levodropropizine | Dompé S.p.A. (IT) | 2004-12-28 | — | — | US | disclosed |
| EP-1307441-B1 | 1,3-DIOXOLANES WITH ANTITUSSIVE ACTIVITY | DOMPE SPA (IT) | 2004-05-06 | — | — | EP | disclosed |
| US-20040038989-A1 | 1,3-dioxolanes with antitussive activity | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-02-26 | — | — | US | disclosed |
| EP-0506235-A1 | Glyceraldehyde-3-pentanide and process for producing same | ELI LILLY AND COMPANY (US) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038989-A1 | 1,3-dioxolanes with antitussive activity | ADRA1D, QDPR, PDE3A | MMP9 1322/4885MMP1 468/4885MMP2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.